ethyl(2,6-dimethoxyphenyl)(oxo)acetate | 14655-34-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl(2,6-dimethoxyphenyl)(oxo)acetate
• 英文别名: Ethyl (2,6-dimethoxyphenyl)(oxo)acetate；ethyl 2-(2,6-dimethoxyphenyl)-2-oxoacetate
• CAS: 14655-34-6
• 化学式: C₁₂H₁₄O₅
• 分子量: 238.24
• InChiKey: JQLPWEAWMMDNTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  145-150 °C(Press: 0.05 Torr)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl(2,6-dimethoxyphenyl)(oxo)acetate 在 甲醇 、 sodium hydroxide 、 potassium tert-butylate 、 水 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 二甲基亚砜 、 甲苯 为溶剂， 反应 101.5h， 生成 1-(2,6-dimethoxyphenyl)cyclopropane-1-carboxylic acid
  参考文献：
  名称：

  WO2006/122403

  摘要：

  公开号：
• 作为产物：
  描述：

  草酰氯单乙酯 在 氰化亚铜 、 lithium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以93%的产率得到ethyl(2,6-dimethoxyphenyl)(oxo)acetate
  参考文献：
  名称：

  WO2006/122403

  摘要：

  公开号：

文献信息

• Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
  申请人：Roux Richard

  公开号：US20050176770A1

  公开（公告）日：2005-08-11

  The invention relates to compounds of formula: and to solvates and/or hydrates thereof, with affinity for and selectivity towards the V 1b receptors or both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to a process for preparing them, to the intermediate compounds of formula (II) which are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.

  本发明涉及式的化合物：以及其溶剂化物和/或水合物，具有亲和力和选择性，对精氨酸加压素的V1b受体或V1a和V1b受体均有亲和力。本发明还涉及制备它们的方法，用于制备它们的有用的式（II）的中间化合物，含有它们的制药组合物以及它们用于制备药物的用途。
• Novel 1,3-dihydro-2h-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them
  申请人：——

  公开号：US20030162767A1

  公开（公告）日：2003-08-28

  The invention relates to compounds of formula: 1 and to solvates and/or hydrates thereof, with affinity for and selectivity towards the V 1b receptors or both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to a process for preparing them, to the intermediate compounds of formula (II) which are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.

  本发明涉及式子1的化合物及其溶剂化物和/或水合物，它们具有亲和力和选择性，可作用于精氨酸加压素的V1b受体或V1a和V1b受体。本发明还涉及制备它们的方法，用于制备它们的有用中间体化合物（II），含有它们的制药组合物以及它们用于制备药物的用途。
• 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them
  申请人：Roux Richard

  公开号：US06864277B2

  公开（公告）日：2005-03-08

  The invention relates to compounds of formula: and to solvates and/or hydrates thereof, with affinity for and selectivity towards the Vreceptors or both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to a process for preparing them, to the intermediate compounds of formula (II) which are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.

  本发明涉及以下公式的化合物：以及其溶剂化物和/或水合物，具有亲和力和选择性，可与精氨酸加压素的V1B和/或V1A受体结合。本发明还涉及一种制备它们的方法，用于制备它们的有用中间体化合物（II）的方法，含有它们的制药组合物以及它们用于制备药物的用途。
• Quinoline derivatives as ep4 antagonists
  申请人：Belley Michel

  公开号：US20090099226A1

  公开（公告）日：2009-04-16

  The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom, a N(O) group or a C(R 5 ) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included.

  本发明涉及喹啉衍生物作为前列腺素E类型受体拮抗剂，用于治疗EP4介导的疾病或症状，如急性和慢性疼痛、骨关节炎、类风湿性关节炎和癌症。这些衍生物具有以下结构式（I）：其中A和B表示氮原子或CH基团，但不能同时为CH，Q可以表示氮原子或碳原子，Y和Z可以是氮原子、N（O）基团或C（R5）基团。还包括含有式（I）的衍生物的制药组合物。
• 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
  申请人：Sanofi-Aventis

  公开号：US07425566B2

  公开（公告）日：2008-09-16

  The invention relates to compounds of formula: and to solvates and/or hydrates thereof, with affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin. The invention also relates to a process for preparing them, to the intermediate compounds of formula (II) which are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.

  本发明涉及以下式的化合物：以及与其溶剂化合物和/或水合物，具有亲和力和选择性，可以结合到加压素的V1b受体或同时结合到V1b和V1a受体。本发明还涉及一种制备它们的方法，以及用于制备药物的中间化合物（II）和含有它们的制药组合物，以及它们的用途。